Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome
https://doi.org/10.14341/omet12980
Abstract
Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach.
About the Authors
E. A. Troshina
National Medical Research Center of Endocrinology
Russian Federation
Russian Federation
Ekaterina A. Troshina, MD, PhD, Professor
Moscow
Р. A. Terekhov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Petr A. Terekhov
Moscow
References
1. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85(5):1319-1340. doi: https://doi.org/10.1016/j.fertnstert.2005.10.054
2. Troshina EA, Pokusaeva VN, Andreeva EN, et al. Ozhirenie u zhenshhin. Ed by Mel’nichenko GA, Nikiforovskogo NK. Moscow: OOO «Izdatel’stvo «Medicinskoe informacionnoe agentstvo»; 2017. — 272 p. (In Russ.).
3. Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJM. 2003;96(7):521-529. doi: https://doi.org/10.1093/qjmed/hcg086
4. Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71(4):929-931. doi: https://doi.org/10.1210/jcem-71-4-929
5. Rozhivanov RV, Bobkov DN, Kurbatov DG. Pathogenetic factors of disorders in spermatogenesis and antioxidative activity of an ejaculate in young men with post pubertal visceral obesity and normal andrological anamnesis. Obesity and metabolism. 2019;16(3):76-80. (In Russ.). doi: https://doi.org/10.14341/omet10054
6. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab. 1993;76(5):1140-1146. doi: https://doi.org/10.1210/jcem.76.5.8496304
7. Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260-1271. doi: https://doi.org/10.1016/j.jsxm.2018.06.012
8. Longcope C, Kato T, Horton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest. 1969;48(12):2191-2201. doi: https://doi.org/10.1172/JCI106185
9. Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary-adrenal axis in humans. Horm Metab Res. 2000;32(11-12):521-525. doi: https://doi.org/10.1055/s-2007-978680
10. Bjorntorp P. Centralization of body fat P. In: International textbook of obesity. Chichester (UK): John Wiley & Sons; 2001. P. 213-224.
11. Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002 Jul;26(7):938-41. doi: https://doi.org/10.1038/sj.ijo.0802022. PMID: 12080446.
12. Rebuffé-Scrive M, Lundholm K, Björntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest. 1985;15(5):267-271. doi: https://doi.org/10.1111/j.1365-2362.1985.tb00182.x
13. Houseknecht KL, Mantzoros CS, Kuliawat R, et al. Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes. 1996;45(11):1638-1643. doi: https://doi.org/10.2337/diab.45.11.1638
14. Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology. 2004;145(6):2613-2620. doi: https://doi.org/10.1210/en.2004-0032
15. Vettor R, De Pergola G, Pagano C, et al. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. Eur J Clin Invest. 1997;27(12):1016-1024. doi: https://doi.org/10.1046/j.1365-2362.1997.2270773.x
16. Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997;100(4):808-813. doi: https://doi.org/10.1172/JCI119595
17. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-2641. doi: https://doi.org/10.1210/jc.2004-2190
18. Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-709. doi: https://doi.org/10.2337/diabetes.50.4.707
19. Pagotto U, Gambineri A, Pelusi C, et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88(9):4139-4143. doi: https://doi.org/10.1210/jc.2003-030554
20. Cryer A. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Int J Biochem. 1981;13(5):525-541. doi: https://doi.org/10.1016/0020-711x(81)90177-4
21. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80(1):239-243. doi: https://doi.org/10.1210/jcem.80.1.7829619
22. Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002;26(7):938-941. doi: https://doi.org/10.1038/sj.ijo.0802022
23. Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-116. doi: https://doi.org/10.1530/EJE-15-0262
24. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.x
25. Bolezni zhirovoj tkani. Ed. by Dedov II. Moscow: GEOTAR-Media; 2020. 224 p. (In Russ.). doi: https://doi.org/10.33029/9704-5367-4-BOL-1-224
26. Alexandersen P, Christiansen C. The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis. 2004;173(2):157-169. doi: https://doi.org/10.1016/S0021-9150(03)00242-9
27. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1-7. doi: https://doi.org/10.1080/tam.6.1.1.7
28. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401
29. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15. doi: https://doi.org/10.3109/13685538.2015.1004049
30. Rossijskaja associacija jendokrinologov. Klinicheskie rekomendacii. Deficit testosterona (gipogonadizm) u muzhchin s saharnym diabetom. Moscow; 2019. (In Russ.)]. Доступно по: https://cr.rosminzdrav.ru. Ссылка активна на 11.05.2023.
31. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. [Erratum in: J Clin Endocrinol Metab. 2021;106(7):e2848] doi: https://doi.org/10.1210/jc.2009-2354
32. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507-514. doi: https://doi.org/10.1530/EJE-08-0601
33. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131-143. doi: https://doi.org/10.2174/157339912799424573
34. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058. doi: https://doi.org/10.1210/jc.2011-2591
35. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381-394. doi: https://doi.org/10.1111/j.1365-2265.2005.02350.x
36. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20-28. doi: https://doi.org/10.4065/82.1.20
37. Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289-305. doi: https://doi.org/10.1097/01.pra. et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.x
38. Behre HM, Tammela TLJ, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 mo. Aging Male. 2012;15(4):198-207. doi: https://doi.org/10.3109/13685538.2012.699562
39. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650. doi: https://doi.org/10.1210/jc.2009-1251
Supplementary files
|
|
1. Figure 1. Algorithm of decision-making on the start of hypogonadism therapy | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(406KB)
|
Indexing metadata ▾ | |
Review
For citations:
Troshina E.A., Terekhov Р.A. Hypogonadism and visceral obesity in men are full–fledged components of the metabolic syndrome. Obesity and metabolism. 2023;20(1):84-91. (In Russ.) https://doi.org/10.14341/omet12980
Views:
6254
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
